Imagine a world where advanced cancers, once deemed untreatable, could be pushed into long-term remission or even cured. This is no longer just a dream—it’s becoming a reality thanks to groundbreaking T cell therapies. Researchers from Rutgers Cancer Institute, New Jersey’s sole National Cancer Institute (NCI)-designated Comprehensive Cancer Center, and RWJBarnabas Health, alongside colleagues from the National Cancer Institute, have unveiled remarkable findings from two HPV-related studies. These studies reveal the transformative potential of novel T cell therapies to achieve lasting remission and complete tumor regression in patients battling advanced epithelial cancers. But here’s where it gets even more exciting: these therapies are showing unprecedented long-term gains, offering hope where there was once little.
Led by Dr. Christian Hinrichs, Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute, these studies were presented at the Society for Immunotherapy of Cancer (SITC 2025) Annual Meeting in National Harbor, Maryland. In one study, researchers shared interim results from a Phase II clinical trial involving genetically engineered T cell receptor (TCR)-T cells designed to target the HPV16 E7 oncoprotein—a key player in HPV-associated cancers. The treatment protocol included a conditioning regimen, a single infusion of up to 50 billion E7 T cells, and adjuvant aldesleukin.
The 10 patients in this trial were facing advanced, often incurable cancers with limited treatment options. Among them were individuals with head and neck cancer, cervical cancer, anal cancer, and esophageal cancer. Remarkably, six out of 10 patients experienced significant tumor shrinkage, and two achieved complete tumor regression that has persisted for 11 and 12 months, respectively. What’s even more astonishing? Both of these patients had already tried immunotherapy and other standard treatments without success. This raises a provocative question: Could T cell therapies become the new frontier in cancer treatment, even for the most stubborn cases?
Dr. Hinrichs emphasized the significance of these findings, stating, ‘Metastatic HPV-associated cancers remain a formidable challenge, but our results show that E7-directed T cells can induce meaningful, and sometimes complete, responses in patients with limited options. This is a promising step toward effective engineered T cell therapies for these and other epithelial cancers.’
The development of this treatment is a testament to collaboration, with the National Cancer Institute and Rutgers Cancer Institute working together seamlessly. The phase II study was conducted at Rutgers Cancer Institute, leveraging its on-site Good Manufacturing Practices (GMP) facility to produce the cell products. This unique infrastructure positions the Center as a leader in advancing novel cell therapies, bridging the gap between laboratory discoveries and patient care.
Maria, a patient from Philadelphia, shared her transformative experience: ‘When I finished my treatment, I couldn’t believe how quickly I started feeling better. Within a month, the nodules were gone, and for the first time in years, I felt free, full of energy, and truly alive. I can spend time with my son, do the things I love, and enjoy life again. I’m so grateful to the team that made this possible and proud to be living proof of the difference their research can make.’
But here’s where it gets controversial: In a second study, investigators reported that two patients with metastatic cervical cancer remain in complete remission a full decade after receiving a single infusion of tumor-infiltrating lymphocyte (TIL) therapy. Is this the beginning of a new era in cancer treatment, or is it too early to declare victory? These findings, part of clinical trial NCT01585428, provide the strongest evidence to date that cellular therapy can produce long-term, potentially curative responses in epithelial cancers—the most common type of malignancy.
A decade after treatment, these patients showed no evidence of disease through imaging and circulating tumor DNA analysis. The administered T cells underwent a temporary expansion phase, coinciding with tumor shrinkage and apparent elimination. Strikingly, tumor responses persisted long after the initial T cell activity, suggesting the tumors were cleared during the initial response.
Dr. Steven K. Libutti, Director of Rutgers Cancer Institute, highlighted the importance of NCI-designated Comprehensive Cancer Centers like Rutgers: ‘Centers like ours bring together the scientific expertise, clinical resources, and collaborative environment needed to translate discoveries from the lab into clinical trials and, ultimately, into life-changing treatments for patients.’
Sue, a patient from Washington, DC, who has remained cancer-free for 12 years, shared her story: ‘Participating in this clinical trial felt like a calling. My cancer was very advanced, and I wanted to use whatever time I had left to contribute to research that could help others. I never imagined the treatment would work for me, but just two months after my TIL infusion, my cancer was undetectable on scans. Now, 12 years later, I’m still cancer-free and deeply grateful. It’s an incredible blessing to see how my participation has led to new discoveries with the potential to help others.’
Dr. Hinrichs concluded, ‘These studies demonstrate that one-time cell therapies can achieve durable responses in epithelial cancers, which have historically been more resistant to these treatments than blood cancers. The decade-long complete responses to TIL therapy give hope that these patients may be cured. The E7 T cell results, including complete responses, are encouraging and support further exploration of this approach.’
But what do you think? Are we on the cusp of a cancer treatment revolution, or are these findings too good to be true? Share your thoughts in the comments below and join the conversation about the future of cancer therapy.
